Tecentriq + ctDNA 测试提高了膀胱癌患者在手术后存活率,根据2025年ESMO数据。 Tecentriq plus ctDNA testing improved survival in bladder cancer patients after surgery, per 2025 ESMO data.

Roche的Tecentriq在外科手术后可检测到CtDNA的肌肉侵入性膀胱癌患者中,根据在2025年ESMEO大会上介绍的第三阶段IMvigor011试验结果,总体和无疾病存活率有所改善。 Roche’s Tecentriq improved overall and disease-free survival in muscle-invasive bladder cancer patients with detectable ctDNA after surgery, according to phase III IMvigor011 trial results presented at ESMO Congress 2025. Tecentriq利用Natera的信号测试指导治疗, 将死亡风险降低41%, Using Natera’s Signatera test to guide treatment, Tecentriq reduced the risk of death by 41% and recurrence or death by 36% versus placebo. 总体存活率为32.8个月与21.1个月之比,中位无疾病存活率为9.9个月与4.8个月之比。 Median overall survival was 32.8 months vs. 21.1 months, and median disease-free survival was 9.9 months vs. 4.8 months. 阴性CtDNA患者的复发风险低,避免了不必要的治疗。 Patients with negative ctDNA had a low recurrence risk, avoiding unnecessary treatment. 林业发展局正在审查Signatera作为配套诊断。 The FDA is reviewing Signatera as a companion diagnostic.